RNA vaccine study for recurrent medulloblastoma
Part of Cancer clinical trials.
This trial tests a personalized RNA vaccine for children and young adults whose medulloblastoma has come back. The vaccine is made from your own tumor material and aims to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 39 years old.
- You have medulloblastoma that has returned at least once after previous treatment.
- You have had radiation therapy as part of your earlier treatment.
- You need to have surgery to collect a sample of your tumor for the vaccine.
- You must be able to have an MRI scan of your brain and spine before and after surgery.
- You need to be on a seizure medication (like levetiracetam) during the vaccine treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This trial tests a new personalized RNA vaccine made from your own tumor tissue. It is designed to help your immune system fight the cancer after it has returned. You will have surgery to collect the tumor, and then the vaccine is given to try to stop the tumor from growing again.
This trial tests a personalized vaccine made from your own tumor tissue. The goal is to help your immune system fight cancer and to improve the response to PD-1 inhibitor therapy.
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Hear when a new Recurrent Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.